<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431415</url>
  </required_header>
  <id_info>
    <org_study_id>RAXSIA</org_study_id>
    <nct_id>NCT03431415</nct_id>
  </id_info>
  <brief_title>Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer</brief_title>
  <acronym>RAXSIA</acronym>
  <official_title>Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is disease free survival rate at 5 years in stage IA2
      (T1aN0M0 or T1bN0M0 only) non-small cell lung cancer (NSCLC) patients treated either by
      surgery or stereotactic body radiation therapy (SBRT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Today, the best medical literature available confirms that surgery is superior to radiation
      therapy in the treatment of the early stage lung cancer. However, good emerging data
      demonstrates potential equality between these two treatments. Two major international studies
      have tried to compare both treatments but have failed to complete the study because of the
      lack of patients accrual. We chose to design a trial in which patients will be part of a
      shared decision making process in selecting the treatment modality.

      Patients with early stage lung cancer, that can undergo surgical treatment will be offered
      SBRT, and in conjunction with the pulmonologist will decide which treatment they prefer. We
      intend to complete the recruitment of patients within 02 years, then follow-up for 5 more
      years to collect data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2018</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>To compare the disease free survival of patients with Stage up to IA2 (T1aN0M0 or T1bN0M0) NSCLC managed either by SBRT or surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival rate at 5 years in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of morbidity</measure>
    <time_frame>5 years</time_frame>
    <description>Level of morbidity in both arms (CTCAE 4.0 - common toxicity criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of efficacy in the SBRT arm</measure>
    <time_frame>5 years</time_frame>
    <description>Level of efficacy in the SBRT arm (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL assessment</measure>
    <time_frame>5 years</time_frame>
    <description>QOL assessment with SF36 questionnaire (pre and post treatment) in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 and DLCO decline at 1-year post-treatment in both arms</measure>
    <time_frame>1 year</time_frame>
    <description>FEV1 or DLCO decline at 1-year post-treatment in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic evaluation in both arms</measure>
    <time_frame>5 years</time_frame>
    <description>Health economic evaluation in both arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Non-small Cell Lung Cancer Stage I</condition>
  <condition>Surgery</condition>
  <condition>Stereotactic Body Radiation Therapy</condition>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients that will undergo surgery (anatomical segmentectomy, lobectomy or bilobectomy) as primary lung cancer treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT (Stereotactic Body Radiation Therapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients that will undergo SBRT as primary lung cancer treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anatomical Segmentectomy, Lobectomy or Bilobectomy</intervention_name>
    <description>Lung Cancer Anatomical Resection</description>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy</intervention_name>
    <description>SBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.</description>
    <arm_group_label>SBRT (Stereotactic Body Radiation Therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-75

          -  Pathologically (histologically or cytologically) proven NSCLC.

          -  Stage IA2 T1aN0M0 or T1bN0M0 only, fit for surgery.

               -  Tumor ≤ 2 cm (T1a or T1b according to AJCC, 8th ed.)

          -  Hilar or mediastinal lymph nodes ≤ 1 cm with no abnormal hilar or mediastinal uptake
             on PET scan are considered N0.

               -  Patients with hilar or mediastinal lymph nodes &gt; 1 cm on CT scan or abnormal PET
                  scan (including suspicious but non-diagnostic uptake) are eligible, provided
                  directed tissue biopsies by EBUS or mediastinoscopy of all abnormally identified
                  areas are negative for cancer.

               -  EBUS preferable

               -  No regional or distant metastases.

          -  Resectable disease and treatable by SBRT

          -  Peripherally located tumor.

               -  Primary tumor within or touching the zone of the proximal bronchial tree, defined
                  as a volume of 2 cm in all directions around the proximal bronchial tree are
                  excluded (carina, right and left main bronchi, right and left upper lobe bronchi,
                  intermedius bronchus, right middle lobe bronchus, lingular bronchus, right and
                  left lower lobe bronchi).

               -  No involvement of the central pleura and/or structures of the mediastinum.

          -  Staging studies must be done within 8 weeks prior to study entry

          -  Patients must provide study specific informed consent prior to study entry.

        Exclusion Criteria:

          -  Previously operated lung cancer.

          -  Previous thoracic irradiation.

          -  Patients with a history of other malignancies, except: adequately treated non-melanoma
             skin cancer, curatively treated in-situ cancer, or other solid tumors curatively
             treated with no evidence of disease for ≥ 5 years following the end of treatment and
             which, in the opinion of the treating physician, do not have a substantial risk of
             recurrence of the prior malignancy.

          -  Pulmonary nodule manifested as pure ground-glass opacity.

          -  Severe pulmonary hypertension.

          -  Severe cardiac, hepatic or renal insufficiency.

          -  Severe peripheral vascular disease.

          -  Severe cerebral or psychiatric pathologies.

          -  Severe chronic heart disease.

          -  Life expectancy &lt; 6 months.

          -  Pregnant or lactating woman.

          -  Unwilling to have follow-up.

          -  Central tumor where pneumonectomy might be considered.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula A Ugalde Figueroa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor, Thoracic Surgeon, Research Coordinator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula A Ugalde Figueroa, MD</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>5503</phone_ext>
    <email>paula.ugalde@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arthur Vieira, MD</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>5524</phone_ext>
    <email>arthur.vieira@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôtel-Dieu de Québec (CHUQ)</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1R2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Dagnault, MD</last_name>
      <phone>+1(418)525-4444</phone>
      <email>anne.dagnault@mail.chudequebec.ca</email>
    </contact>
    <investigator>
      <last_name>Anne Dagnault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Université Laval</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Ugalde, MD</last_name>
      <phone>4186568711</phone>
      <phone_ext>5511</phone_ext>
      <email>paula.ugalde@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Arthur Vieira, MD</last_name>
      <phone>4186568711</phone>
      <phone_ext>5524</phone_ext>
      <email>arthur.vieira@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Arthur Vieira, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Labbé, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves Lacasse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annie Roy, Inf</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reda Haouari, Inf</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</investigator_affiliation>
    <investigator_full_name>Paula Antonia Ugalde Figueroa</investigator_full_name>
    <investigator_title>Research Coordinator (Thoracic Surgery)</investigator_title>
  </responsible_party>
  <keyword>Lung</keyword>
  <keyword>Cancer</keyword>
  <keyword>Early-Stage</keyword>
  <keyword>Video-assisted Thoracic Surgery</keyword>
  <keyword>VATS</keyword>
  <keyword>SBRT</keyword>
  <keyword>Stereotactic Body Radiation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

